We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+47.5%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow %
91.48%
Top 10 Hldgs %
25%
Holding
94
New
94
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
IRD
Opus Genetics
IRD
+$14.3M
2
ANAB icon
AnaptysBio
ANAB
+$6.34M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.78M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.47M
5
INSM icon
Insmed
INSM
+$5.43M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 85.32%
2 Technology 2.23%
3 Consumer Staples 1.19%
4 Financials 1.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
76
Tango Therapeutics
TNGX
$4.41B
$1.37M 0.51%
+120,000
New +$1.26M
ATYR
77
aTyr Pharma
ATYR
$50.1M
$1.29M 0.48%
+332,258
New +$1.21M
VRCA icon
78
Verrica Pharmaceuticals
VRCA
$87.3M
$1.25M 0.47%
+10,879
New +$1,000K
BLSA
79
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$1.11M 0.42%
+100,000
New +$1.07M
NMTR
80
DELISTED
9 Meters Biopharma
NMTR
$1.09M 0.41%
+63,250
New +$1.06M
ROCCU
81
DELISTED
Roth CH Acquisition II Co. Unit
ROCCU
$1.04M 0.39%
+100,000
New +$1.03M
CNSP icon
82
CNS Pharmaceuticals
CNSP
$7.86M
$951K 0.36%
+1
New +$1.85M
FATBW
83
DELISTED
FAT Brands Inc. Warrant
FATBW
$810K 0.3%
+300,000
New +$572K
VINCW
84
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
$710K 0.27%
+215,250
New +$716K
CHAQ.WS
85
DELISTED
Chardan Healthcare Acquisition 2 Corp. Warrants, entitling the holder thereof to purchase one-half (
CHAQ.WS
$495K 0.18%
+500,000
New +$378K
CEREW
86
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$365K 0.14%
+64,666
New +$261K
IMTXW
87
DELISTED
Immatics N.V. Warrants
IMTXW
$281K 0.1%
+97,467
New +$279K
JSPRW icon
88
Japer Therapeutics Warrants
JSPRW
$236K 0.09%
+162,500
New +$204K
KBNT
89
DELISTED
Kubient, Inc. Common Stock
KBNT
$236K 0.09%
+42,269
New +$175K
GLEO.WS
90
DELISTED
Galileo Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Ordinary Share
GLEO.WS
$168K 0.06%
+200,000
New +$125K
VERO
91
DELISTED
Venus Concept
VERO
$162K 0.06%
+568
New +$212K
QTNT
92
DELISTED
Quotient Limited Ordinary Shares
QTNT
$130K 0.05%
+623
New +$145K
OBIO icon
93
Orchestra BioMed
OBIO
$254M
$128K 0.05%
+10,000
New +$114K
LYRA
94
DELISTED
LYRA THERAPEUTICS INC
LYRA
$59K 0.02%
+104
New +$58.6K
1 2 3
4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Altium Capital Management, which disclosed 94 positions worth $268M. Its ten largest holdings account for 25% of the portfolio.

Its largest position is Opus Genetics: 2,068,530 shares worth $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, followed by Technology and Consumer Staples.

  • Altium Capital Management's largest Q4 2020 buy was Opus Genetics: 2,068,530 shares worth $13.4M.
  • Altium Capital Management's ten largest holdings make up 25% of its $268M portfolio in Q4 2020.
  • Altium Capital Management disclosed 94 positions in Q4 2020, its first 13F filing on record.

Based on Altium Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.